Latest Breaking News On - Seagen padcev - Page 1 : comparemela.com

Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline

Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesKristen drakeDaiichi sankyoJulie cunninghamSeagen padcevDamini chokshiPeter dannenbaumBioxcel therapeutics incExchange commissionMerck research laboratoriesAmerican society of clinical oncologyGeorgetown universityAgensys incPfizer incStatement of merck co incMerck co inc

Novartis s MorphoSys Acquisition Comes With Cancer Drugs & Antitrust Questions

Novartis’s €2.7B acquisition of MorphoSys brings two cancer drug candidates, one of which would give the pharmaceutical giant a way to stand apart from other myelofibrosis treatments. In a separate deal, MorphoSys sold to Incyte its rights to a partnered blood cancer drug.

United statesMonjuvi minjuviBiovitrum vonjoSeagen padcevIncyte jakafi jakaviAndrew berensAmerican society of hematologyConstellation pharmaceuticalsEuropean commissionAmerican societyLeerink partnersFederal trade commissionSwedish orphan biovitrumWeight lossMedical devicesHealthcare innovation

Pfizer shows little enthusiasm for Abrysvo sales of $515M Q4

Pfizer shows little enthusiasm for Abrysvo sales of $515M Q4
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United kingdomLee brownAlbert bourlaEdward jonesSamir malikSeagen padcevJohn boylanDavid dentonArena pharmaceuticalsHealthcare conferenceThird bridge

FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

RAHWAY, N.J. (BUSINESS WIRE) Dec 15, 2023

United statesJulie cunninghamSeagen padcevPeter dannenbaumDamini chokshiChrissy trankEuropean society for medical oncology congressPatient support programStatement of merck co incPfizer incAgensys incExchange commissionMerck access programSeagen incMerck co incDrug administration

The Biotech Growth Trust Plc - Half-year Report

LONDON STOCK EXCHANGE ANNOUNCEMENT The Biotech Growth Trust PLC.

United statesHong kongCity ofUnited kingdomJosh golombHamish baillieGeoff hsuAmgen blincytoKatherine mansonEli lillyKeymed biosciencesRoche lunsumioNovarti zolgensmaRoger yatesSeagen padcevVentyx biosciences